Sandoz (SIX:SDZ / OTCQX:SDZNY), the global leader in affordable medicines, announced it will host its 2026 capital markets day on Tuesday, September 8, from 13:30 to 17:00 UK time at the London Stock Exchange. The event, which will be webcast live and available here, aims to detail the company's strategy to maximize value in what it terms the 'golden decade for biosimilars.'
Biosimilars are lower-cost versions of biologic drugs, which are among the most expensive treatments for chronic and life-threatening diseases such as cancer, rheumatoid arthritis, and diabetes. As patent expirations on many top-selling biologics loom over the next decade, Sandoz—which pioneered the biosimilars market 20 years ago—is positioning itself to capture significant market share. The company's portfolio includes approximately 1,300 medicines, from common cold treatments to cancer therapies, and it reached over one billion patients in 2025, generating net sales of USD 11.1 billion.
The capital markets day comes at a critical time for the pharmaceutical industry. With global healthcare systems under pressure to contain costs, biosimilars offer a pathway to reduce spending while maintaining treatment efficacy. Sandoz's focus on affordable medicines aligns with policy efforts worldwide to improve access to biologics. The company's growth strategy is driven by its purpose: pioneering access for patients.
In addition to the London event, Sandoz plans to host an investor and analyst site visit in Slovenia from November 9-10, providing further insight into its new biosimilars development and supply-chain hub. Attendance for both events is by invitation only on a first-come, first-served basis, with invitations to be distributed in due course. The site visit will not be webcast.
The announcement underscores the growing importance of biosimilars in the pharmaceutical landscape. As Sandoz celebrates 20 years of pioneering biosimilars, 80 years of antibiotics manufacturing, and 140 years of heritage in 2026, the company is leveraging its experience to drive future growth. With a workforce of over 20,000 colleagues from 100 nationalities, Sandoz aims to continue its mission of ensuring patients worldwide have access to essential medicines.
Investors and analysts will be keen to hear details on Sandoz's pipeline, regulatory milestones, and market expansion plans during the capital markets day. The company's forward-looking statements, as outlined in the release, caution that actual outcomes may vary due to risks including global economic conditions, exchange rates, legal provisions, and competitive activities. Nonetheless, the event is expected to provide a clear roadmap for how Sandoz intends to capitalize on the biosimilars opportunity in the coming years.
